TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07797153: A Randomized, Controlled, Open-Label, Multi-center, Phase III Study of JSKN033 Versus Investigator's Choice of Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Platinum-Based Chemothe

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 368 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07797153 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07797153 Rescue Dossier →